Pfizer to build R&D capacity in China
Pfizer will expand its clinical services and biomedical presence in China as part of a worldwide effort to develop its R&D infrastructure.
Working with the government, the US firm will partner with the Wuhan National Bioindustry Base Construction and Management office to establish a clinical R&D centre to provide support for ongoing trial programmes.
Allan Gabor, president of Pfizer’s operations in North Asia, said the unit “will be an integral part of Pfizer's global R&D operations while being closely aligned with the Chinese government's strategy on biopharmaceutical industry development.”
Pfizer also unveiled plans to expand its existing R&D facility in Shanghai.
The US drug giant joins Germany’s Merck KGaA which, earlier this week, also announced plans for its own €150m ($224m) clinical R&D hub in Beijing.
